

Richard M Bergenstal

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6726374/richard-m-bergenstal-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

17,286
citations

51
h-index

131
g-index

136
ext. papers

21,418
ext. citations

11.6
avg, IF

6.63
L-index

#	Paper	IF	Citations
128	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2012 , 35, 1364-79	14.6	2713
127	Diabetes and cancer: a consensus report. <i>Diabetes Care</i> , 2010 , 33, 1674-85	14.6	1251
126	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019 , 42, 1593-1603	14.6	998
125	International Consensus on Use of Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2017 , 40, 1631-1640	14.6	872
124	Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. <i>Diabetes Care</i> , 2015 , 38, 971-8	14.6	863
123	State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 66-72	8.1	751
122	Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. <i>New England Journal of Medicine</i> , 2010 , 363, 311-20	59.2	664
121	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 371-378	27.4	537
120	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <i>Lancet, The</i> , 2010 , 376, 431-9	40	503
119	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , 2009 , 32, 187-92	14.6	500
118	Threshold-based insulin-pump interruption for reduction of hypoglycemia. <i>New England Journal of Medicine</i> , 2013 , 369, 224-32	59.2	479
117	Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1407-1408	27.4	377
116	Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 155-163	8.1	350
115	Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. <i>Diabetes Care</i> , 2013 , 36, 2009-14	14.6	341
114	The T1D Exchange clinic registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4383-9	5.6	328
113	Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. <i>Diabetes Care</i> , 2019 , 42, 400-405	14.6	293
112	Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. <i>Diabetes Care</i> , 2012 , 35, 787-93	14.6	237

111	Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2017 , 167, 365-374	8	233
110	Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. <i>Diabetes Care</i> , 2010 , 33, 428-33	14.6	232
109	Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2018 , 41, 2275-2280	14.6	215
108	Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3411-9	5.6	211
107	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). <i>Diabetes Care</i> , 2014 , 37, 3235-43	14.6	210
106	The Fallacy of Average: How Using HbA Alone to Assess Glycemic Control Can Be Misleading. <i>Diabetes Care</i> , 2017 , 40, 994-999	14.6	200
105	Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. <i>Lancet, The</i> , 2018 , 392, 1321-1329	40	183
104	The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. <i>Journal of Diabetes Science and Technology</i> , 2019 , 13, 614-626	4.1	162
103	REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 538-545	14.6	152
102	Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels. <i>Annals of Internal Medicine</i> , 2017 , 167, 95-102	8	151
101	Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. <i>Diabetes Care</i> , 2008 , 31, 1305-10	14.6	140
100	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). <i>Diabetes Care</i> , 2015 , 38, 2217-25	14.6	134
99	Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. <i>Diabetes Technology and Therapeutics</i> , 2008 , 10, 149-59	8.1	132
98	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018 , 41, 2552-2559	14.6	109
97	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2017 , 40, 777-783	14.6	102
96	Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control. <i>Diabetes Technology and Therapeutics</i> , 2018 , 20, 314-316	8.1	99
95	The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. <i>American Journal of Medicine</i> , 2005 , 118, 1S-6S	2.4	96
94	Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers!. <i>Diabetes Care</i> , 2015 , 38, 1615-21	14.6	95

93	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 603-10	14.6	90
92	Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. <i>The Diabetes Educator</i> , 2000 , 26, 981-9	2.5	88
91	Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. <i>Diabetes Care</i> , 2011 , 34, 2403-5	14.6	86
90	Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetes Care</i> , 2017 , 40, 1614-1621	14.6	85
89	Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. <i>Journal of Diabetes Science and Technology</i> , 2013 , 7, 562-78	4.1	81
88	Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, S4-S11	8.1	81
87	Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. <i>Diabetes Care</i> , 2017 , 40, 554-560	14.6	80
86	Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. <i>Diabetes Care</i> , 2020 , 43, 250-260	14.6	76
85	A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. <i>Lancet, The</i> , 2021 , 397, 208-219	4.0	74
84	Advances in technology for management of type 1 diabetes. <i>Lancet, The</i> , 2019 , 394, 1265-1273	4.0	71
83	Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 700-708	18.1	69
82	Trends in Insulin Use and Diabetes Control in the U.S.: 1988-1994 and 1999-2012. <i>Diabetes Care</i> , 2016 , 39, e33-5	14.6	68
81	Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetes Care</i> , 2015 , 38, 716-22	14.6	60
80	Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults. <i>Journal of the Endocrine Society</i> , 2018 , 2, 1320-1337	0.4	52
79	Continuous Glucose Monitoring in Patients With Type 1 Diabetes Using Insulin Injections. <i>Diabetes Care</i> , 2016 , 39, e81-2	14.6	51
78	Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. <i>American Journal of Medicine</i> , 2010 , 123, 374.e 9 -18	2.4	45
77	Improving the clinical value and utility of CGM systems: issues and recommendations : A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetologia</i> , 2017 , 60, 2319-2328	10.3	44
76	Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetologia</i> , 2015 , 58, 868-70	10.3	44

75	Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4356-4364	5.6	42
74	Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical Practice. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, S217-S225	8.1	40
73	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 391-399	8.1	36
72	Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery. <i>Diabetes Care</i> , 2019 , 42, 1344-1347	14.6	36
71	Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). <i>Diabetes Therapy</i> , 2012 , 3, 13	3.6	35
70	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 2262-2272	27.4	33
69	Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 329-38	6.4	31
68	Threshold insulin-pump interruption to reduce hypoglycemia. <i>New England Journal of Medicine</i> , 2013 , 369, 1474	59.2	31
67	The Digital/Virtual Diabetes Clinic: The Future Is Now-Recommendations from an International Panel on Diabetes Digital Technologies Introduction. <i>Diabetes Technology and Therapeutics</i> , 2021 , 23, 146-154	8.1	31
66	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA).	10.3	30
65	Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2019 , 393, 1138-1148	40	28
64	Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. <i>Diabetes Care</i> , 2015 , 38, 1558-66	14.6	28
63	Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. <i>Current Medical Research and Opinion</i> , 2008 , 24, 639-44	2.5	28
62	Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 1630-1640	14.6	26
61	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 121-128	6.7	25
60	Can a tool that automates insulin titration be a key to diabetes management?. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 675-82	8.1	25
59	Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. <i>Diabetologia</i> , 2020 , 63, 229-241	10.3	22
58	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). <i>Pediatric Diabetes</i> , 2020 , 21, 1375-1393	3.6	21

57	The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 1-5	8.1	21
56	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. <i>Diabetes Care</i> , 2015 , 38, 1627-33	14.6	20
55	Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. <i>Endocrine Practice</i> , 2009 , 15, 326-34	3.2	20
54	Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab013	0.4	18
53	Continuous glucose monitoring: transforming diabetes management step by step. <i>Lancet, The</i> , 2018 , 391, 1334-1336	4.0	17
52	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. <i>Diabetes Care</i> , 2021 , 44, 1586-1594	14.6	16
51	Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 273-285	8.1	14
50	Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. <i>Current Medical Research and Opinion</i> , 2011 , 27, 2335-42	2.5	14
49	Time Savings Using a Standardized Glucose Reporting System and Ambulatory Glucose Profile. <i>Journal of Diabetes Science and Technology</i> , 2018 , 12, 614-621	4.1	14
48	Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data. <i>Diabetes Care</i> , 2019 , 42, e60-e61	14.6	13
47	Advanced Technology in the Management of Diabetes: Which Comes First-Continuous Glucose Monitor or Insulin Pump?. <i>Current Diabetes Reports</i> , 2019 , 19, 50	5.6	13
46	Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. <i>BMJ Open</i> , 2017 , 7, e016738	3	13
45	Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. <i>Diabetes Technology and Therapeutics</i> , 2011 , 13, 601-6	8.1	13
44	International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm. <i>Diabetes Management</i> , 2011 , 1, 175-189	0	12
43	Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network. <i>Diabetes</i> , 2018 , 67, 1689-P	0.9	12
42	HbA: The Glucose Management Indicator, Time in Range, and Standardization of Continuous Glucose Monitoring Reports in Clinical Practice. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020 , 49, 95-107	5.5	12
41	Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. <i>Journal of Diabetes Science and Technology</i> , 2015 , 9, 1016-20	4.1	11
40	Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, e38-e39	14.6	11

39	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <i>European Endocrinology</i> , 2014 , 10, 23-30	3.4	11
38	Continuous Glucose Monitoring-Derived Data Report-Simply a Better Management Tool. <i>Diabetes Care</i> , 2020 , 43, 2327-2329	14.6	10
37	Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 851-7	8.1	9
36	Diabetes Telehealth Solutions: Improving Self-Management Through Remote Initiation of Continuous Glucose Monitoring. <i>Journal of the Endocrine Society</i> , 2020 , 4, bvaa076	0.4	8
35	Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. <i>Diabetes Technology and Therapeutics</i> , 2020 , 22, 853-860	8.1	7
34	Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring. <i>Diabetes/Metabolism Research and Reviews</i> , 2017 , 33, e2879	7.5	7
33	Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization. <i>Endocrine Practice</i> , 2012 , 18, 371-5	3.2	7
32	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> , 2021 , 44, 2729-2737	14.6	6
31	Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.. <i>Lancet Diabetes and Endocrinology</i> , 2022	18.1	6
30	EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS. <i>Endocrine Practice</i> , 2019 , 25, 306-314	3.2	5
29	InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. <i>Diabetes Therapy</i> , 2020 , 11, 1017-1027	3.6	5
28	Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1906-1913	6.7	4
27	Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 50-4	2.1	4
26	Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. <i>Current Medical Research and Opinion</i> , 2011 , 27, 531-40	2.5	4
25	Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care. <i>Journal of Diabetes Science and Technology</i> , 2021 , 15, 539-545	4.1	4
24	Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. <i>Diabetes Technology and Therapeutics</i> , 2021 , 23, 857-861	8.1	4
23	Type 2 Diabetes in Adults 2011 , 77-137		3
22	Beyond A1C-Standardization of Continuous Glucose Monitoring Reporting: Why It Is Needed and How It Continues to Evolve. <i>Diabetes Spectrum</i> , 2021 , 34, 102-108	1.9	3

21	Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System. <i>Diabetes Technology and Therapeutics</i> , 2021 , 23, 828-836	8.1	3
20	Insulin Titration Algorithms Incorporated into a Patient Glucose Diary Result in Significant Improvements in Glucose Profiles and A1C. <i>Diabetes</i> , 2018 , 67, 710-P	0.9	2
19	Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1330-1331	27.4	2
18	Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2021 , 23, 20-30	8.1	2
17	Addressing shortfalls of laboratory HbA using a model that incorporates red cell lifespan. <i>ELife</i> , 2021 , 10,	8.9	2
16	International Diabetes Center: COVID-19 Won't Stop Us From Fulfilling Our Mission. <i>Journal of Diabetes Science and Technology</i> , 2020 , 14, 725-726	4.1	1
15	1280-P: Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care. <i>Diabetes</i> , 2019 , 68, 1280-P	0.9	1
14	Response to Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. <i>Diabetes Care</i> 2018;41:2275-2280. <i>Diabetes Care</i> , 2019 , 42, e29-e30	14.6	1
13	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. <i>Diabetologia</i> , 2021 , 64, 935-938	10.3	1
12	Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2572-2581	6.7	1
11	Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System. <i>Diabetes Technology and Therapeutics</i> , 2021 , 23, 791-798	8.1	1
10	Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes.. <i>Journal of Diabetes and Its Complications</i> , 2021 , 108106	3.2	1
9	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 50	8.7	1
8	Continuous Ketone Monitoring Consensus Report 2021. <i>Journal of Diabetes Science and Technology</i> , 2021 , 19322968211042656	4.1	0
7	Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C). <i>Postgraduate Medicine</i> , 2021 , 133, 253-264	3.7	0
6	Insulin dosing guidance to optimise type 2 diabetes management - AuthorsPreply. <i>Lancet, The</i> , 2019 , 394, 1321	4.0	
5	Trial of a New Diabetes Education Model: Closing the Gap in Health Disparity for People with Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021 , 15, 568-574	4.1	
4	Initiating Insulin in the Emergency Center and Urgent Care to Prevent Hospital Admission for Patients with Hyperglycemia: A Unique Insulin Starter Kit. <i>Journal of Diabetes Science and Technology</i> , 2021 , 15, 755-761	4.1	

- 3 Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. *Journal of Diabetes Science and Technology*, **2021**, 19322968211016513^{4.1}
- 2 Response to Comment on Aleppo et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. *Diabetes Care* 2021;44:2729-2737.. *Diabetes Care*, **2022**, 45, e85-e86 14.6
- 1 Primary Care and Diabetes Technologies and Treatments.. *Diabetes Technology and Therapeutics*, **2022**, 24, S143-S158 8.1